Chart courtesy of stockcharts

Shares of NUVO fell nearly 20% in extended trading after said Tuesday German drug developer Bayer AG is pulling out of the companies' collaboration over blood-clot treatment candidate alfimeprase, and Nuvelo will resume development of the drug on its own. This new for sure it will have some impact in share price tomorrow morning, so pay attention to this one.

Disclaimer : Trading stocks involves risk, this information should not be viewed as trading recommendations.The charts provided here are not meant for investment purposes and only serve as technical examples.